Limits...
Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.

Hus I, Bojarska-Junak A, Chocholska S, Tomczak W, Woś J, Dmoszyńska A, Roliński J - PLoS ONE (2013)

Bottom Line: Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL.Th17 percentages positively correlated with iNKT and adversely with Treg cells.The results of this study suggest that Th17 may play a beneficial role in CLL immunity.

View Article: PubMed Central - PubMed

Affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.

ABSTRACT
Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development. The purpose of this study was to evaluate the role of Th17 cells and IL17A in biology of CLL. The study group included 294 untreated CLL patients in different clinical stages. Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL. Th17 cells' percentages in PB were lower in patients who died due to CLL during follow-up due to CLL (as compared to surviving patients) and in patients responding to first-line therapy with fludarabine-based regimens (as compared to non-responders). IL-17A inversely correlated with the time from CLL diagnosis to the start of therapy and was lower in patients who required treatment during follow-up. Th-17 and IL-17A values were lower in patients with adverse prognostic factors (17p and 11q deletion, CD38 and ZAP-70 expression). CLL patients with detectable IL-17A mRNA in T cells were in Rai Stage 0 and negative for both ZAP-70 and CD38 expression. Th17 percentages positively correlated with iNKT and adversely with Treg cells. The results of this study suggest that Th17 may play a beneficial role in CLL immunity.

Show MeSH

Related in: MedlinePlus

Plasma levels of IL-17A and percentage of Th17 cells in CLL patients and HVs.(A) The IL-17A concentration in PB from CLL patients an healthy volunteers (HVs) (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018). (B) The percentage of CD4+/CD3+/IL-17A+ (Th17) cells in CLL and HVs (8.76% vs. 3.02%, p = 0.035).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3815235&req=5

pone-0078091-g002: Plasma levels of IL-17A and percentage of Th17 cells in CLL patients and HVs.(A) The IL-17A concentration in PB from CLL patients an healthy volunteers (HVs) (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018). (B) The percentage of CD4+/CD3+/IL-17A+ (Th17) cells in CLL and HVs (8.76% vs. 3.02%, p = 0.035).

Mentions: The IL-17A concentration in PB was significantly higher in CLL patients than in HV (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018) (Figure 2A). There were no significant differences in IL-17A plasma levels between PB and BM (39.35 pg/ml vs. 37.10 pg/ml) in CLL patients (p = 0.059). The plasma level of IL-17A inversely correlated with the stage of disease (R = −0.259; p = 0.006). CLL patients with Rai Stage 0 had significantly higher levels of IL-17A (median: 44.63 pg/ml) than those with Rai Stages I–II (median: 35.33 pg/ml) or III–IV (median: 15.23 pg/ml) (Figure 3A). A significantly higher median plasma IL-17A level was observed in ZAP-70-negative patients in comparison to ZAP-70-positive patients (45.36 pg/ml vs. 26.11 pg/ml, p = 0.0062) (Figure 4A). Likewise, we observed a significantly higher plasma IL-17A level in CD38-negative patients in comparison to CD38-positive patients (39.73 pg/ml vs. 29.25 pg/ml, p = 0.033) (Figure 4B). The plasma levels of IL-17A inversely correlated with the levels of TNF (R = −0.286; p = 0.039) and IL-10 (R = −0.551; p = 0.0001).


Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.

Hus I, Bojarska-Junak A, Chocholska S, Tomczak W, Woś J, Dmoszyńska A, Roliński J - PLoS ONE (2013)

Plasma levels of IL-17A and percentage of Th17 cells in CLL patients and HVs.(A) The IL-17A concentration in PB from CLL patients an healthy volunteers (HVs) (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018). (B) The percentage of CD4+/CD3+/IL-17A+ (Th17) cells in CLL and HVs (8.76% vs. 3.02%, p = 0.035).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3815235&req=5

pone-0078091-g002: Plasma levels of IL-17A and percentage of Th17 cells in CLL patients and HVs.(A) The IL-17A concentration in PB from CLL patients an healthy volunteers (HVs) (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018). (B) The percentage of CD4+/CD3+/IL-17A+ (Th17) cells in CLL and HVs (8.76% vs. 3.02%, p = 0.035).
Mentions: The IL-17A concentration in PB was significantly higher in CLL patients than in HV (39.35 pg/ml vs. 14.94 pg/ml, p = 0.0018) (Figure 2A). There were no significant differences in IL-17A plasma levels between PB and BM (39.35 pg/ml vs. 37.10 pg/ml) in CLL patients (p = 0.059). The plasma level of IL-17A inversely correlated with the stage of disease (R = −0.259; p = 0.006). CLL patients with Rai Stage 0 had significantly higher levels of IL-17A (median: 44.63 pg/ml) than those with Rai Stages I–II (median: 35.33 pg/ml) or III–IV (median: 15.23 pg/ml) (Figure 3A). A significantly higher median plasma IL-17A level was observed in ZAP-70-negative patients in comparison to ZAP-70-positive patients (45.36 pg/ml vs. 26.11 pg/ml, p = 0.0062) (Figure 4A). Likewise, we observed a significantly higher plasma IL-17A level in CD38-negative patients in comparison to CD38-positive patients (39.73 pg/ml vs. 29.25 pg/ml, p = 0.033) (Figure 4B). The plasma levels of IL-17A inversely correlated with the levels of TNF (R = −0.286; p = 0.039) and IL-10 (R = −0.551; p = 0.0001).

Bottom Line: Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL.Th17 percentages positively correlated with iNKT and adversely with Treg cells.The results of this study suggest that Th17 may play a beneficial role in CLL immunity.

View Article: PubMed Central - PubMed

Affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.

ABSTRACT
Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development. The purpose of this study was to evaluate the role of Th17 cells and IL17A in biology of CLL. The study group included 294 untreated CLL patients in different clinical stages. Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL. Th17 cells' percentages in PB were lower in patients who died due to CLL during follow-up due to CLL (as compared to surviving patients) and in patients responding to first-line therapy with fludarabine-based regimens (as compared to non-responders). IL-17A inversely correlated with the time from CLL diagnosis to the start of therapy and was lower in patients who required treatment during follow-up. Th-17 and IL-17A values were lower in patients with adverse prognostic factors (17p and 11q deletion, CD38 and ZAP-70 expression). CLL patients with detectable IL-17A mRNA in T cells were in Rai Stage 0 and negative for both ZAP-70 and CD38 expression. Th17 percentages positively correlated with iNKT and adversely with Treg cells. The results of this study suggest that Th17 may play a beneficial role in CLL immunity.

Show MeSH
Related in: MedlinePlus